We’re on a Mission to Improve the Human Condition

Combining cutting-edge data science and human genetics, we’re creating precision medicines to fight debilitating diseases.

Learn About Our Company
IT’S ALL POSSIBLE.

We leverage an innovative drug discovery model to accelerate the identification of novel molecular targets and create effective precision medicine treatments with more efficiency than ever before.

We’re Rewriting the Narrative
to Change the Future

Neuron23 Envisions a World Where Every Disease has a Treatment Through Breakthrough Science, Powered by Personalized Medicine

Our Science

Meet the Heart of Neuron23

We're a diverse team with proven success in both science and business, driven by one common goal: enhancing and improving the lives of the patients we serve. Compassion is at our core, and we're on a never-ending mission to create the type of breakthroughs that can propel the world forward.

Meet Our Team

Latest News

  • NEWS /

    Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease

    NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027 SOUTH SAN FRANCISCO, Calif. – June 24, 2025 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of […]

    Read More
  • NEWS /

    Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology

    SOUTH SAN FRANCISCO, Calif. – March 25, 2025 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the publication of a manuscript in the Proceedings of the National Academy of Sciences (PNAS), which explores the role of tyrosine kinase 2 (TYK2) inhibition in […]

    Read More
  • NEWS /

    Neuron23 to Present Phase 1 Healthy Volunteer Data of NEU-411, a Brain-penetrant LRRK2 Inhibitor, at AD/PD™ 2025

    SOUTH SAN FRANCISCO, Calif. – March 24, 2025 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced that data from the Phase 1 healthy volunteer study of NEU-411 will be presented at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), taking […]

    Read More
See All News

Be in the Room When History is Made

We're looking for team members with an insatiable hunger for creating change and the talent to make it happen — those ready to meet us where we are and excited to help take us where we want to go.

Current Opportunities